作者: Marie-Anne von Schillde , Gabriele Hörmannsperger , Monika Weiher , Carl-Alfred Alpert , Hannes Hahne
DOI: 10.1016/J.CHOM.2012.02.006
关键词:
摘要: The intestinal microbiota has been linked to inflammatory bowel diseases (IBD), and oral treatment with specific bacteria can ameliorate IBD. One bacterial mixture, VSL#3, containing Lactobacillus, Bifidobacterium, Streptococcus, was clinically shown reduce inflammation in IBD patients normalize levels of IP-10, a lymphocyte-recruiting chemokine, murine colitis model. We identified Lactobacillus paracasei prtP-encoded lactocepin as protease that selectively degrades secreted, cell-associated, tissue-distributed resulting significantly reduced lymphocyte recruitment after intraperitoneal injection an ileitis A human casei isolate also found encode degrade IP-10. L. casei feeding studies model (T cell transferred Rag2(-/-) mice) revealed prtP-disruption mutant less potent reducing IP-10 levels, T cell infiltration and inflammation cecal tissue compared the isogenic wild-type strain. Thus, lactocepin-based therapies may be effective treatments for chemokine-mediated like